Biotech Stocks

Upcoming PDUFA Dates Could Be Major Catalysts For These 3 Biotech Stocks

In the biotech realm, the author of today’s article notes that “PDUFA (Prescription Drug User Fee Act) dates – the deadline of the FDA’s review of new drugs – determine whether a treatment is fit for purpose or not and a yay or nay can act as a major catalyst to send shares either soaring or crashing.” As such, he… 

Better Know These Lesser-Known Biotech Stocks That Have Been Surging

As the biotech sector has received increased investor focus over the past year amid the COVID-19 pandemic, the author of today’s article notes that “Even the smaller and lesser known are being seen now as having immense potential; Many of these companies are working tirelessly toward new drug developments and eyeing larger collaborations.” With that, she proceeds to highlight three… 

A Diamond In The Rough & 2 Other Top Biotech Stock Picks For 2021

One of the strongest biotechs out there, a diamond in the rough, and a high-risk, high-reward play make up the three biotech stocks identified by the author of today’s article as top picks for 2021 for investors looking for even better biotech returns than those offered by broad biotech ETFs such as the SPDR S&P Biotech ETF. For a look… 

With Many Psychedelic Stocks Posting Triple-Digit Returns, The “Shroom Boom” May Just Be Beginning

While biotech stocks have been hot over the last year, today’s article notes that another group of stocks have been trading like biotech companies of late: psychedelic stocks. In fact, a slew of psychedelic stocks have posted triple-digit returns over the last year – and with the impending release of studies examining the use of psychedelics to treat mental health… 

Invest In Biotech – Rationally – With These 5 Picks

Noting how difficult it can be for investors to understand what’s happening in the biotech industry generally and at specific biotech companies, the author of today’s article explains that he tends to invest “in companies that have a track record of working with existing products while successfully developing pipelines of new products” and in “picks-and-shovels companies that get paid to… 

While Some Biotech/Drug Stocks Were Hit Hard By COVID This Year, These 6 Thrived Because Of It

While the pharma/biotech sector was not spared COVID-19 pain this year, with various companies hit hard by disruptions in clinical studies and delays in elective surgeries and in individuals seeking medical care, the authors of today’s article note that “some biotech stocks have more than doubled during this period, especially those focusing on developing a coronavirus vaccine.” They proceed to… 

What Could Cause These 3 Biotech Stocks To Explode Higher Next Year – And What Could Go Wrong

Compelling clinical trial data and decisions from the FDA could send one, two, or all three of the biotech stocks highlighted in today’s article through the roof next year. For a look at each of these three biotech stocks and their respective catalysts – as well as a consideration of the potential pitfalls associated with each of them – CLICK… 

“A Rare Opportunity In The Small Biotech Sector”

Today’s article highlights “a low-risk, high-quality small biotech with high growth potential.” More specifically, this “is a revolutionary biotech company that uses tissue engineering to treat/repair sports-related injuries and severe burns” – and while it was negatively impacted this year by the canceling and delaying of elective surgeries due to COVID-19, the author outlines why rapid growth should return in… 

A Range Of Catalysts Suggest A Bright 2021 For Biotech

Biotech bulls see a bright year ahead for the sector thanks to a range of catalysts outside of COVID. As today’s article explains, “Among the most closely tracked catalysts are the potential approval of Biogen Inc.’s experimental drug for Alzheimer’s disease, expectations for a rebound in deal-making activity, and innovations from gene therapy updates to next-generation cancer technologies.” For more… 

Non-Coronavirus-Vaccine Biotech Stocks Making Big Moves – And Worth Watching Heading Into 2021

“In light of all the focus on a coronavirus vaccine, most people tend to overlook the other happenings in the industry,” notes the author of today’s article. He reminds us that, even in the midst of a global pandemic, research has continued on treatments and drugs for cancers, genetic diseases, rare diseases and more – and he highlights three biotech…